Neuromodulators

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (12:39, 5 June 2023) (edit) (undo)
 
(6 intermediate revisions not shown.)
Line 76: Line 76:
**Noradrenaline
**Noradrenaline
**Carmoterol, see [[2y02]].
**Carmoterol, see [[2y02]].
-
**Salbutamol (Albuterol in USA), [[2y04]].
+
**[[Salbutamol]] (Albuterol in USA), [[2y04]].
*Beta blockers:
*Beta blockers:
**Metoprolol
**Metoprolol
Line 94: Line 94:
*G<sub>s</sub>: adenylate cyclase activated, cAMP up. For G<sub>s</sub> see [[Beta2 adrenergic receptor-Gs protein complex updated]].
*G<sub>s</sub>: adenylate cyclase activated, cAMP up. For G<sub>s</sub> see [[Beta2 adrenergic receptor-Gs protein complex updated]].
β2-adrenergic agonists:
β2-adrenergic agonists:
-
**Salbutamol (Albuterol in USA)
+
**[[Salbutamol]] (Albuterol in USA)
**Bitolterol mesylate
**Bitolterol mesylate
-
**Formoterol
+
**[[Formoterol]]
**Isoprenaline
**Isoprenaline
**Levalbuterol
**Levalbuterol
**Metaproterenol
**Metaproterenol
-
**Salmeterol
+
**[[Salmeterol]]
**Terbutaline
**Terbutaline
**Ritodrine
**Ritodrine
Line 116: Line 116:
===[[Monoamine oxidase]]===
===[[Monoamine oxidase]]===
===[[Monoamine oxidase b]]===
===[[Monoamine oxidase b]]===
 +
 +
=Dopamine=
 +
==[[DOPA decarboxylase]]==
 +
==Dopamine Receptors==
 +
'''Dopamine receptors''' are a class of metabotropic G protein-coupled receptors that are important in the central nervous system. Dopamine receptors are involved in many neurological processes that comprise motivation, pleasure, cognition, memory, learning, and fine motor skills. There are five subtype dopamine receptors, D1, D2, D3, D4, and D5. The D3 receptor is a part of the D2-like family.<ref>PMID:15148138</ref>
 +
*[[Dopamine receptor|Dopamine receptors 1 page]]
 +
*[[Dopamine Receptors|Dopamine receptors 2 page]]
 +
===Agonists===
 +
*Amphetamine<ref>Jones S, Kornblum JL, Kauer JA (August 2000). "Amphetamine blocks long-term synaptic depression in the ventral tegmental area". J. Neurosci. 20 (15): 5575–80. PMID 10908593. http://www.jneurosci.org/cgi/pmidlookup?view=long&pmid=10908593.</ref>
 +
*Methamphetamine<ref>Cruickshank, CC.; Dyer, KR. (Jul 2009). "A review of the clinical pharmacology of methamphetamine.". Addiction 104 (7): 1085–99. doi:10.1111/j.1360-0443.2009.02564.x. PMID 19426289.</ref>
 +
 +
===Antagonists===
 +
*Clebopride<ref>Cuena Boy R, Maciá Martínez MA (1998). "[Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System]" (in Spanish). Atencion Primaria 21 (5): 289–95. PMID 9608114. Free full text</ref>
 +
*Nafadotride<ref>Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 agonist. Nature. 1999;400:371–375.</ref>
 +
*Eticlopride.
 +
 +
<scene name='47/475982/Cv/1'>Structure of the human dopamine D3 receptor in complex with the antagonist eticlopride and maltose</scene> ([[3pbl]]).
 +
 +
<scene name='47/475982/Cv/5'>Eticlopride binding site</scene>.
 +
==Parkinson's disease==
 +
DOPA decarboxylase is responsible for the synthesis of '''[http://en.wikipedia.org/wiki/Dopamine ''dopamine'']''' and [http://en.wikipedia.org/wiki/Serotoninn ''serotonin''] from '''[http://en.wikipedia.org/wiki/L-dopa ''L-DOPA'']''' and [http://en.wikipedia.org/wiki/L-5-Hydroxytryptophan ''L-5-hydroxytryptophan''], respectively. It is highly stereospecific, yet relatively nonspecific in terms of substrate, making it a somewhat uninteresting enzyme to study. Although it is not typically a rate-determining step of dopamine synthesis, the decarboxylation of L-DOPA to dopamine by DDC is the controlling step for individuals with '''[http://en.wikipedia.org/wiki/Parkinson%27s_disease ''Parkinson's disease'']'''<ref name="hadjiiconstantinou">PMID:1904055 </ref>, the second most common neurodegenerative disorder, occuring in 1% of the population over the age of 65. The loss of dopaminergic neurons is the main cause of cognitive impairment and tremors observed in patients with the disease. The hallmark of the disease is the formation of [http://en.wikipedia.org/wiki/alpha-synuclein ''alpha-synuclein''] containing [http://en.wikipedia.org/wiki/Lewy_body ''Lewy bodies''].
 +
 +
Currently, treatment for the disease is aimed at DOPA decarboxylase inhibition. Since dopamine cannot cross the blood-brain barrier, it cannot be used to directly treat Parkinson's disease. Thus, exogenously administered L-DOPA is the primary treatment for patients suffering from this neurodegenerative disease. Unfortunately, DOPA decarboxylase rapidly converts L-DOPA to dopamine in the blood stream, with only a small percentage reaching the brain. By inhibiting the enzyme, greater amounts of exogenously administered L-DOPA can reach the brain, where it can then be converted to dopamine. <ref name="burkhard">PMID:11685243 </ref>. Unfortunately, with continued L-Dopa treatment, up to 80% of patients experience 'wearing-off' symptoms, dyskinesias and other motor complications (referred to as the "on-off phenomenon". <ref name="lees">PMID:1904055 </ref>. Clearly, a better understanding of the catalytic mechanism and enzymatic activity of DDC in both healthy and PD individuals is critical to drug design and treatment of the disease.
 +
 +
=GABA=
 +
==GABA receptors==
 +
'''GABA''' (i.e. gamma-aminobutyric acid) is the primary inhibitory neurotransmitter of the vertebrate central nervous system. GABA can bind one of two different receptor proteins, each using a discrete mechanism to elicit a cellular response. Upon binding with GABA, '''GABAB receptors''' (metabotropic) utilize a second messenger amplification pathway that ultimately results in an inhibitory signal for neuronal transmission. This pathway for signal transmission differs from [[GABAA receptors]] (ionotropic), which are considered ligand-gated ion channels as the binding of GABA results in the opening of ion channels leading to the inhibition of a neuronal signal.
 +
<scene name='82/829381/Cv/9'>GABA bound to the GABAB receptor</scene> (PDB code [[4ms3]]).
 +
*[[GABA receptor]]
 +
*[[User:Rana Saad/The human GABAb receptor]]
 +
*[[GABAA receptor]]
 +
==[[GABA(A) receptor-associated protein]]==
 +
 +
=Histamine=
 +
<scene name='82/829381/Cv/5'>Histamine</scene>.
 +
==Histamine receptors==
 +
Allergy symptoms are mostly caused by the release of histamine in response to allergens. The binding of histamine to the extracellular portion of the H1 receptor triggers a structural change of the transmembrane portion, leading to a change in the C terminal area. This c terminal region interacts with G proteins, leading to the activation of the Gq signalling pathway, which triggers allergy symptoms like itchy eyes and runny noses. Many allergy drugs are anti-histamines, in that they bind to the histamine receptor but do not cause the conformational change that leads to a response. The H1 receptor is a histamine receptor belonging to the family of rhodopsin-like G-protein-coupled receptors. The H1 receptor is linked to an intracellular G-protein (G<sub>q</sub>) that activates [[phospholipase C]] (see [[PLC beta 3 Gq|Unique bidirectional interactions of Phospholipase C beta 3 with G alpha Q]] and the inositol triphosphate (IP3) signalling pathway. When a ligand binds to a G protein-coupled receptor that is coupled to a G<sub>q</sub> heterotrimeric G protein, the α-subunit of G<sub>q</sub> can bind to and induce activity in the PLC isozyme PLC-β, which results in the cleavage of PIP2 into IP3 and DAG.
 +
*[[Histamine H1 receptor]]
 +
* [[3rze]] - human histamine H1 receptor with an antagonist doxepin.
 +
 +
=Serotonin=
 +
==Serotonin receptors==
 +
'''5-hydroxytryptamine (5-HT), Serotonin receptors''' are found on the membrane of neurons in the central nervous system and peripheral nervous system. These receptors allow for the body to respond to serotonin and regulate many biological pathways. Serotonin, also known as 5 hydroxytryptamine, is an endogenous neurotransmitter made from tryptophan and is largely found in the gastrointestinal tract. It is known to regulate mood, appetite, digestion, circadian rhythm, learning and internal temperature regulation. It is can be an inhibitory or excitatory neurotransmitter that is released into the synaptic space and can bind to receptors on the postsynaptic neuron or be taken back up into the presynaptic neuron via Serotonin re-uptake transporters.<ref>Goodsell D. ''Serotonin Receptor''. RCSB PDB-101 (2013) [http://www.rcsb.org/pdb/101/motm.do?momID=164 DOI: 10.2210/rcsb_pdb/mom_2013_8]</ref> 5-HT receptors are classified into 7 different subfamilies (5-HT1, 5-HT2, 5-HT3, etc.) by signaling mechanisms and homology of structure. All 5-HT receptors are known to have G-protein linked pathways except for the 5-HT3 receptor which acts as an ion channel. <ref name ="one">Wang C, Jiang Y, Ma J, Wu H, Wacker D, Katritch V, Han GW, Liu W, Huang XP, Vardy E, McCorvy JD, Gao X, Zhou EZ, Melcher K, Zhang C, Bai F, Yang H, Yang L, Jiang H, Roth BL, Cherezov V, Stevens RC, Xu HE. Structural Basis for Molecular Recognition at Serotonin Receptors. Science. 2013 May 3; 340(6132): 610–614. PMID:3644373 [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644373/]</ref>
 +
===[[5-hydroxytryptamine receptor|Serotonin receptors, main page]]===
 +
===[[5-hydroxytryptamine receptor 3D structures|3D structures of Serotonin receptors]]===
 +
===[[5-ht3a receptor|5-HT3A receptor]]===
 +
==[[Serotonin Transporter]]==
 +
==See also [[Serotonin N-acetyltransferase]]==
 +
=Nitric Oxide=
 +
Neuronal Nitric Oxide Synthase ([[Nos1]]) is functioning in cell signaling and communication - a vital part of the nervous tissue.
</StructureSection>
</StructureSection>
== References ==
== References ==
<references/>
<references/>

Current revision

Structure of the human dopamine D3 receptor in complex with the antagonist eticlopride and maltose, 3pbl

Drag the structure with the mouse to rotate

References

  1. Martin JL, Begun J, McLeish MJ, Caine JM, Grunewald GL. Getting the adrenaline going: crystal structure of the adrenaline-synthesizing enzyme PNMT. Structure. 2001 Oct;9(10):977-85. PMID:11591352
  2. Huang J, Chen S, Zhang JJ, Huang XY. Crystal structure of oligomeric beta1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol. 2013 Apr;20(4):419-25. doi: 10.1038/nsmb.2504. Epub 2013 Feb, 24. PMID:23435379 doi:10.1038/nsmb.2504
  3. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol. 2004 May;61(5):641-4. PMID:15148138 doi:10.1001/archneur.61.5.641
  4. Jones S, Kornblum JL, Kauer JA (August 2000). "Amphetamine blocks long-term synaptic depression in the ventral tegmental area". J. Neurosci. 20 (15): 5575–80. PMID 10908593. http://www.jneurosci.org/cgi/pmidlookup?view=long&pmid=10908593.
  5. Cruickshank, CC.; Dyer, KR. (Jul 2009). "A review of the clinical pharmacology of methamphetamine.". Addiction 104 (7): 1085–99. doi:10.1111/j.1360-0443.2009.02564.x. PMID 19426289.
  6. Cuena Boy R, Maciá Martínez MA (1998). "[Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System]" (in Spanish). Atencion Primaria 21 (5): 289–95. PMID 9608114. Free full text
  7. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 agonist. Nature. 1999;400:371–375.
  8. Miles EW. The tryptophan synthase alpha 2 beta 2 complex. Cleavage of a flexible loop in the alpha subunit alters allosteric properties. J Biol Chem. 1991 Jun 15;266(17):10715-8. PMID:1904055
  9. Burkhard P, Dominici P, Borri-Voltattorni C, Jansonius JN, Malashkevich VN. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase. Nat Struct Biol. 2001 Nov;8(11):963-7. PMID:11685243 doi:http://dx.doi.org/10.1038/nsb1101-963
  10. Miles EW. The tryptophan synthase alpha 2 beta 2 complex. Cleavage of a flexible loop in the alpha subunit alters allosteric properties. J Biol Chem. 1991 Jun 15;266(17):10715-8. PMID:1904055
  11. Goodsell D. Serotonin Receptor. RCSB PDB-101 (2013) DOI: 10.2210/rcsb_pdb/mom_2013_8
  12. Wang C, Jiang Y, Ma J, Wu H, Wacker D, Katritch V, Han GW, Liu W, Huang XP, Vardy E, McCorvy JD, Gao X, Zhou EZ, Melcher K, Zhang C, Bai F, Yang H, Yang L, Jiang H, Roth BL, Cherezov V, Stevens RC, Xu HE. Structural Basis for Molecular Recognition at Serotonin Receptors. Science. 2013 May 3; 340(6132): 610–614. PMID:3644373 [1]

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Personal tools